GlassScriptPhysician profile
Stanley R Watson
NPI 1164524005
$12,367.41
in general payments reported to CMS, 2019-2025
68 companies · $1,938 in 2025
The $1,938 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,005 · 2020: $2,122 · 2021: $1,960 · 2022: $836 · 2023: $1,562 · 2024: $1,945 · 2025: $1,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,287 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,287.32 |
| Education | $157.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,581.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,182.22 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,130.15 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $798.99 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $719.59 | 2019-2025 | |
| Lilly USA, LLC | $603.13 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $502.33 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $439.93 | 2019-2025 | Trintellix, Gattex |
| Janssen Pharmaceuticals, INC | $434.17 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $323.53 | 2019-2025 | Veozah, Myrbetriq |
| Corcept Therapeutics | $274.31 | 2024-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $260.54 | 2019-2025 | Xifaxan, Trulance |
| Supernus Pharmaceuticals, INC. | $247.38 | 2022-2023 | Qelbree |
| Sanofi-Aventis U.S. LLC | $240.86 | 2019-2022 | |
| Allergan, INC. | $216.90 | 2019-2020 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.